Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ε-Viniferin pentaacetate is an **acetylated derivative** of ε-viniferin, a stilbenoid polyphenol and dimer of resveratrol. It is produced as an **intermediate compound** during the synthesis and purification of ε-viniferin from resveratrol. The compound is formed by acetylating crude ε-viniferin-enriched fractions with acetic anhydride and triethylamine in dichloromethane/DMSO, yielding a pentaacetate with five acetyl groups. This acetylation step serves a **purification purpose**, as the acetylated form can be more easily isolated via column chromatography, followed by hydrolysis with potassium hydroxide to regenerate pure ε-viniferin. ε-Viniferin pentaacetate has been studied for its **biological effects**, showing slight reduction in cell proliferation while potentially offering protection from cell degeneration. The parent compound ε-viniferin exhibits diverse biological activities including antibacterial, antibiofilm, antioxidant, and neuroprotective properties. The synthesis method using ruthenium(III) chloride as an oxidizing agent produces ε-viniferin as the major product, which is then converted to its pentaacetate form for purification purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ε-viniferin pentaacetate.